Neurofeedback
Other30 sessions of theta/beta neurofeedback within 10 weeks.
Other names: biofeedback
NCT Number: NCT01363544
Attention Deficit Hyperactivity Disorder (ADHD) is a developmental disorder that has a severe impact on a child's life and society. The core symptoms are attention problems, hyperactivity and impulsivity. These symptoms are related to disruptions in neurocognitive functions (such as inhibition: the ability to stop behavior) and disruptions in cortical regulation (such as 'cortical underarousal' as measured with the electroencephalogram). To date, the only evidence-based treatment is pharmacological. Medication is not effective in 20-30% of the children with ADHD and it can have side effects. The lack of alternatives for medication is a severe problem for these children and society.
Neurofeedback is becoming increasingly popular for treating ADHD. Neurofeedback is a training in which a person learns to alter its cortical regulation. Neurofeedback has been classified as 'probably effective' but its treatment effects need further empirical evidence. Non specific training effects, such as individual attention, may also contribute to treatment success. In this research project the investigators compare the efficacy of neurofeedback with exercise, a second non-pharmacological treatment, that may be comparable with neurofeedback in terms of non-specific effects. Exercise is also a promising treatment because of its positive effects on behavior, neurocognition in several patient groups. For these reasons, exercise deserves systematic research in ADHD. Furthermore, the investigators compare the efficacy of these two treatments with an optimal pharmacological treatment with methylphenidate (MPH). The main question is if neurofeedback and exercise are comparable in efficacy with MPH for treating ADHD. The primary outcome measure is behaviour (symptoms of ADHD). Secondary outcome measures include neurocognition and cortical regulation. This research project will give answer to the question if neurofeedback and exercise are as effective as MPH. Furthermore, it will give insight in how these interventions will give rise to improvements in behavior.
Looking for future studies?
Notify Me7 year–13 year
All sexes
Interventional
Phase 2 / Phase 3
GGZ InGeest, Amsterdam, North Holland, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
30 sessions of theta/beta neurofeedback within 10 weeks.
Other names: biofeedback
30 sessions of individual sports training during 10 weeks.
Other names: sports
The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
Other names: Not applicable, a generic form will be used.
Time frame: Within 2 weeks after the end of treatment (T1) and 6 months after the end of treatment (T2)
Behaviour is assessed with rating scales (SWAN, SDQ, SDSC,DCD) and actigraphy
Time frame: Within 2 weeks after the end of treatment (T1) and 6 months after the end of treatment (T2)
Neuorcognition is assessed with several neuropsychological tests measuring inhibition, working memory, time estimation and probabilistic learning
Time frame: Within 2 weeks after the end of treatment (T1) and 6 months after the end of treatment (T2)
Neurophysiology is measured with ERPs and quantitative EEG
R. van Mourik
Other
Train Your Brain? Exercise and Neurofeedback Intervention for ADHD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02209116
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder (ADHD)
Manchester, Greater Manchester, United Kingdom
View Trial DetailsNCT06810180
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder (ADHD)
Baltimore, Maryland, United States
View Trial DetailsNCT07521449
ADHD, Attention Deficit Disorder with Hyperactivity
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07376863
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder (ADHD)
Adana, Turkey (Türkiye)
View Trial Details